The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.
Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer.
In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.
Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging.
Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share.
A few of the key primary and secondary sources referred to while preparing the report on the prostate cancer nuclear medicine diagnostics market are the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS).
Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer.
In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.
Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging.
Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share.
A few of the key primary and secondary sources referred to while preparing the report on the prostate cancer nuclear medicine diagnostics market are the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS).
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By Type
1.3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By PET Product
1.3.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By End User
1.3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Prostate Cancer Nuclear Medicine Diagnostics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Prostate Cancer Nuclear Medicine Diagnostics Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Prostate Cancer
5.1.2 Surging Demand for Early and Precise Diagnosis of Prostate Cancer
5.2 Market Restraints
5.2.1 High Cost Related to the Prostate Cancer Diagnostics and Treatment
5.3 Market Opportunities
5.3.1 Growing Use of Radiopharmaceuticals in Prostate Cancer
5.4 Future Trends
5.4.1 Increasing Research Activities for Development of Innovative Imaging Agents
5.5 Impact Analysis
6. Prostate Cancer Nuclear Medicine Diagnostics Market- Global Analysis
6.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis
6.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market, By Geography - Forecast and Analysis
6.3 Company Analysis
6.3.1 Market Positioning of Key Players
6.3.2 Comparative Company Analysis
6.3.3 Growth Strategy Analysis
6.3.4 Performance of Key Players
6.3.4.1 Novartis AG
6.3.4.2 Jubilant Radiopharma
6.3.4.3 Curium
7. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis - By Type
7.1 Overview
7.2 Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)
7.3 SPECT
7.3.1 Overview
7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.4 PET
7.4.1 Overview
7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
8. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis - By PET Product
8.1 Overview
8.2 Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)
8.3 F-18
8.3.1 Overview
8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4 C-11
8.4.1 Overview
8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.5 GA 68 PSMA
8.5.1 Overview
8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9. Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 - End User
9.1 Overview
9.2 Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10. Global Prostate Cancer Nuclear Medicine Diagnostics Market - Geographic Analysis
10.1 North America: Prostate Cancer Nuclear Medicine Diagnostics Market
10.1.1 Overview
10.1.2 North America: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.1.3 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.1.4 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.1.5 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ Million)
10.1.6 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2021 & 2028 (%)
10.1.6.1 US: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.1.1 Overview
10.1.6.1.2 US: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.1.3 US: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.1.6.1.4 US: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.1.6.1.5 US: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ ‘Million)
10.1.6.2 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.2.1 Overview
10.1.6.2.2 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.2.3 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.1.6.2.4 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.1.6.2.5 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ ‘Million)
10.1.6.3 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.3.1 Overview
10.1.6.3.2 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.3.3 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.1.6.3.4 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.1.6.3.5 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ ‘Million)
10.2 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market
10.2.1 Overview
10.2.2 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.3 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type - Revenue and Forecast to 2028 (US$ Million)
10.2.4 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product- Revenue and Forecast to 2028 (US$ Million)
10.2.5 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.2.6 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
10.2.6.1 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.1 Overview
10.2.6.1.2 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.3 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type - Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.4 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product- Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.5 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.2.6.2 France: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.1 Overview
10.2.6.2.2 France: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.3 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type - Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.4 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product- Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.5 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.2.6.3 UK: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.1 Overview
10.2.6.3.2 UK: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.3 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type - Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.4 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product- Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.5 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.2.6.4 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.1 Overview
10.2.6.4.2 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.3 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type - Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.4 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product- Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.5 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.2.6.5 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.1 Overview
10.2.6.5.2 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.3 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type - Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.4 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product- Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.5 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.2.6.6 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.1 Overview
10.2.6.6.2 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.3 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type - Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.4 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product- Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.5 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.3 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market
10.3.1 Overview
10.3.2 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.3 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019- 2028 (US$ Million)
10.3.4 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019- 2028 (US$ Million)
10.3.5 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ million)
10.3.6 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
10.3.6.1 China: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.1.1 Overview
10.3.6.1.2 China: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.1.3 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019- 2028 (US$ Million)
10.3.6.1.4 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019- 2028 (US$ Million)
10.3.6.1.5 China: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ million)
10.3.6.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.2.1 Overview
10.3.6.2.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.2.3 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019- 2028 (US$ Million)
10.3.6.2.4 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019- 2028 (US$ Million)
10.3.6.2.5 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ million)
10.3.6.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.3.1 Overview
10.3.6.3.2 India: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.3.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019- 2028 (US$ Million)
10.3.6.3.4 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019- 2028 (US$ Million)
10.3.6.3.5 India: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ million)
10.3.6.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.4.1 Overview
10.3.6.4.2 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.4.3 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019- 2028 (US$ Million)
10.3.6.4.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019- 2028 (US$ Million)
10.3.6.4.5 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ million)
10.3.6.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.5.1 Overview
10.3.6.5.2 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.5.3 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019- 2028 (US$ Million)
10.3.6.5.4 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019- 2028 (US$ Million)
10.3.6.5.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ million)
10.3.6.6 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.6.1 Overview
10.3.6.6.2 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.6.3 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019- 2028 (US$ Million)
10.3.6.6.4 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019- 2028 (US$ Million)
10.3.6.6.5 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ million)
10.4 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028
10.4.1 Overview
10.4.2 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.3 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.4.4 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.4.5 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ Million)
10.4.6 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2021 & 2028 (%)
10.4.6.1 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.1.1 Overview
10.4.6.1.2 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.1.3 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.4.6.1.4 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.4.6.1.5 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ ‘Million)
10.4.6.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.2.1 Overview
10.4.6.2.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.2.3 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.4.6.2.4 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.4.6.2.5 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ ‘Million)
10.4.6.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.3.1 Overview
10.4.6.3.2 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.3.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.4.6.3.4 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.4.6.3.5 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ ‘Million)
10.4.6.4 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.4.1 Overview
10.4.6.4.2 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ ‘Million)
10.4.6.4.3 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (US$ ‘Million)
10.4.6.4.4 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019- 2028 (US$ ‘Million)
10.4.6.4.5 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (US$ ‘Million)
10.5 South and Central America Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028
10.5.1 Overview
10.5.2 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.5.3 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (USD Million)
10.5.4 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019- 2028 (USD Million)
10.5.5 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (USD Million)
10.5.6 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
10.5.6.1 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.5.6.1.1 Overview
10.5.6.1.2 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.5.6.1.3 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (USD Million)
10.5.6.1.4 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019- 2028 (USD Million)
10.5.6.1.5 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (USD Million)
10.5.6.2 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.5.6.2.1 Overview
10.5.6.2.2 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.5.6.2.3 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (USD Million)
10.5.6.2.4 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019- 2028 (USD Million)
10.5.6.2.5 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019- 2028 (USD Million)
10.5.6.3 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
10.5.6.3.3 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019- 2028 (USD Million)
10.5.6.3.4 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market , by PET Product, 2019- 2028 (USD Million)
10.5.6.3.5 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market , by End User, 2019- 2028 (USD Million)
11. Impact of COVID-19 Pandemic on Global Prostate Cancer Nuclear Medicine Diagnostics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
11.5 South and Central America: Impact Assessment of COVID-19 Pandemic
12. Prostate Cancer Nuclear Medicine Diagnostics Market- Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Blue Earth Diagnostics Limited
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 ImaginAb
13.2.1 1.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Curium
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Jubilant Radiopharma
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 NCM-USA LLC
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 ABX advanced biochemical compounds GmbH
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Telix Pharmaceuticals Ltd.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Novartis AG
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Theragnostics
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Lantheus Medical Imaging, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms
\
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Blue Earth Diagnostics Limited
- ImaginAB
- Curium
- Jubilant Radiopharma
- NCM-USA LLC
- ABX Advanced Biochemical Compounds GmbH
- Telix Pharmaceuticals Ltd.
- Novartis AG
- Theragonostics
- Lantheus Medical Imaging Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | May 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( $ | $ 720.12 million |
| Forecasted Market Value ( $ | $ 1315.66 million |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
